首頁 › 卵巢癌 › 俄克拉荷馬州 › Oklahoma City
Oklahoma City, OK 的 卵巢癌 臨床試驗
28 項針對 卵巢癌 的研究正在 Oklahoma City（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- University of Oklahoma Health Sciences Center, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
招募中1/2 期
- OU Health, Stephenson Cancer Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- University of Oklahoma, Oklahoma City
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
招募中2 期
- OU Health - Stephenson Cancer Center /ID# 277656, Oklahoma City
Study of AVZO-021 in Patients With Advanced Solid Tumors
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
招募中1/2 期
- Stephenson Cancer Center, Oklahoma City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
招募中3 期
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- University of Oklahoma, Oklahoma City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
招募中1/2 期
- OU Health Stephenson Cancer Center, Oklahoma City
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
招募中3 期
- Oklahoma University Health Stephenson Cancer Center, Oklahoma City
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
招募中1 期
- OU Health Stephenson Cancer Center, Oklahoma City
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Oklahoma City
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
招募中
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Study of DM002 in Patients With Advanced Solid Tumors
招募中1/2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- University of Oklahoma - Health Sciences Center, Oklahoma City
Clinical Pre-screening Protocol for Ovarian Cancer
招募中觀察性研究
- OU Health Stephenson Cancer Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
招募中1/2 期
- Stephenson Cancer Center, Oklahoma City
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
招募中2/3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
招募中2 期
- University of Oklahoma, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Stephenson Cancer Center Oklahoma University Health, Oklahoma City
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
招募中歡迎健康志工
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
招募中1 期
- Stephenson Cancer Center, Oklahoma City
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
招募中1 期
- Dren Investigational Site, Oklahoma City
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
招募中2 期
- Stephenson Cancer Center at the University of Oklahoma, Oklahoma City
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
招募中1 期
- Exelixis Clinical Site #13, Oklahoma City
其他城市的 卵巢癌 試驗
- Houston, TX89 項研究
- New York City, NY69 項研究
- Boston, MA61 項研究
- Los Angeles, CA50 項研究
- Nashville, TN49 項研究
- Arlington, VA46 項研究
- Philadelphia, PA44 項研究
- Columbus, OH39 項研究
- St. Louis, MO38 項研究
- Chicago, IL36 項研究
- San Antonio, TX31 項研究
- Cleveland, OH30 項研究
Oklahoma City 的其他研究
- 非小細胞肺癌28 項研究
- 子宮內膜癌25 項研究
- 大腸直腸癌22 項研究
- 前列腺癌21 項研究
- 肺癌19 項研究
- 乳癌17 項研究
- 轉移性癌症16 項研究
- 癌症（所有類型）14 項研究
- 急性髓系白血病14 項研究
- 頭頸部鱗狀細胞癌13 項研究
- 膀胱癌11 項研究
- 胰臟癌11 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。